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Abstract: The proportion of women of reproductive age who are overweight or obese is increasing
globally. Gestational obesity is strongly associated in both human studies and animal models with
early-onset development of adult-associated metabolic diseases including metabolic syndrome in
the exposed offspring. However, animal model studies have suggested that gestational diet in
obese pregnancies is an independent but underappreciated mediator of offspring risk for later life
metabolic disease, and human diet consumption data have highlighted that many women do not
follow nutritional guidelines prior to and during pregnancy. Thus, this review will highlight how
maternal diet independent from maternal body composition impacts the risk for later-life metabolic
disease in obesity-exposed offspring. A poor maternal diet, in combination with the obese metabolic
state, are understood to facilitate pathological in utero programming, specifically through changes in
lipid handling processes in the villous trophoblast layer of the placenta that promote an environment
associated with the development of metabolic disease in the offspring. This review will additionally
highlight how maternal obesity modulates villous trophoblast lipid processing functions including
fatty acid transport, esterification and beta-oxidation. Further, this review will discuss how altering
maternal gestational diet may ameliorate these functional changes in lipid metabolic processes in the
obese placenta.
Keywords: developmental origins of health and disease; gestational diet; maternal body composition;
offspring metabolic health; placenta; lipid metabolism

1. Introduction
Throughout the gestational period, maternal nutrient handling must adapt to the increasing
needs of the growing fetal-placental unit to ensure developmental processes continue in a healthy and
physiological manner. For example, maternal insulin sensitivity diminishes, and fasting serum lipid
levels rise late in gestation to preserve necessary macronutrients for trans-placental transport into fetal
circulation [1–3]. However, there is a fine balance within these physiological metabolic alterations
that, when disrupted by environmental influences, can shift the course of in utero programming to
promote the early life development of metabolic disorders in the offspring. Maternal gestational
obesity is one such environmental influence that has been well associated with poor health outcomes
in exposed offspring. Importantly, recent animal models have highlighted that, in addition to maternal
obesity, a maternal diet high in fat is an important independent regulator of offspring lifelong metabolic
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health. Thus, this review will primarily discuss how maternal gestational dietary composition in obese
pregnancies influences future offspring health independent from maternal body composition.
Furthermore, alterations in lipid processing functions of the placenta—including fatty acid (FA)
transport, lipid esterification and FA beta-oxidation—have been thought to modulate materno-fetal
lipid transport and the resulting changes to fetal lipid exposures may underlie metabolic disease
programming. This review will additionally highlight how maternal obesity modulates these lipid
handling processes in the placenta and discuss how maternal diet may program these placental
processes independently from increased maternal adiposity.
2. Maternal Obesity and Offspring Metabolic Health
The study of the impacts of maternal gestational environment on fetal growth and development is
encompassed within the field of research known as The Developmental Origins of Health and Disease
(DOHaD) [4,5]. This field of study evolved from the observations of Anders Forsdahl and David Barker
in the 1970s and 80s whereby Forsdahl originally described an increased risk of death by coronary
heart disease in those who were relatively impoverished during childhood, but later experienced
prosperity [6]. Barker expanded these observations to include gestational influences and reported that
low birthweight babies were at a greater risk for developing metabolic complications such as obesity,
type 2 diabetes mellitus (insulin resistance) and metabolic syndrome in adulthood [4,5]. This field of
study has since expanded to include the observed increased risk of later life non-communicable diseases
associated with metabolic syndrome in offspring born in an environment of maternal diet-induced
obesity [7,8].
The World Health Organization (WHO) categorizes healthy bodyweight in both adults and
children via body mass index (BMI, kg/m2 ), whereby a BMI > 25 is overweight and a BMI > 30
is obese [9]. The effects of an increased maternal body mass and associated adiposity during the
gestational period on offspring later life health has been extensively documented in humans via
population studies and meta-analyses [10–15]. In line with the DOHaD concept, obesity-exposed
offspring have been found to be at a greater risk for later-life metabolic health issues due in part
to an increased prevalence of having a birthweight that is not appropriate for their gestational age
(AGA) [10,13]. While maternal gestational obesity has largely been associated with infants being born
Large for their Gestational Age (LGA), there has also been a link between maternal obesity and greater
risk of the offspring being born Small for their Gestational Age (SGA) [10,11,14]. Independent from
maternal factors, LGA and SGA offspring are at an increased risk for developing non-communicable
“adult-associated” metabolic disorders as early as four years of age [12,13]. Concerningly, however,
there are reports that children born to obese women are more likely to develop metabolic disorders
regardless of their birthweight, suggesting that maternal body composition during pregnancy influences
offspring metabolic health simply beyond alterations in birthweight [14]. Indeed, recent studies have
suggested that maternal factors including pre-pregnancy BMI may better predict the development of
offspring health complications than birthweight alone [14,15].
The negative influence that maternal adiposity has on offspring metabolic health has additionally
been reported in numerous animal models that attempt to elucidate the mechanisms that lead to
early-life metabolic diseases in obesity-exposed offspring [16,17]. While maternal diet-induced obesity
has been well associated with poor fetal metabolic outcomes in these models, it is important to note
that variations are present in the dietary fat contents and periods of exposure used in these studies
(Table 1). Rodent models in particular have been heavily utilized and the development of metabolic
disorders in the offspring born to high-fat diet (HFD)-induced obese dams has been described the result
of pathological in utero programming [18,19]. The high-fat-exposed rodent offspring have been found
to exhibit an abnormal lipid profiles including hepatic steatosis that ultimately leads to Non-Alcoholic
Fatty Liver Disease (NAFLD) and fibrosis at early life stages [20]. Altered glucose homeostasis is also
prevalent in these obesity-exposed rodent offspring and is manifested as insulin resistance and an
eventual development of type 2 diabetes mellitus (T2DM) during adolescence [21,22]. The altered

Nutrients 2020, 12, 3031

3 of 19

glucose and liver lipid metabolism observed in these offspring has been thought to be a precursor to
the ultimate development of metabolic syndrome in gestational obesity-exposed adolescents [23,24].
Larger mammal species, including sheep, have also been used to study maternal overfeeding and
obesity and its subsequent effects on offspring health and disease. As observed in human meta-analyses
and rodent experiments, sheep offspring exhibit metabolic dysfunction both neonatally and into
adulthood —including increased prevalence of obesity and aberrant lipid and glucose metabolism—in
response to maternal obesity during gestation [25–27]. Additionally, the non-human primate (NHP)
model has been well utilized and describes dysregulated fetal hepatic lipid and glucose metabolism as
an underlying pathology of maternal obesity mediated offspring metabolic disease development [28,29].
Together, these human meta-analyses and animal models demonstrate that maternal obesity during
the gestational period primes the exposed offspring for dysregulated lipid and glucose metabolism
that ultimately results in metabolic disease development early in life.
3. Is Maternal BMI an Accurate Predictor of Offspring Metabolic Health?
The reports from these human and animal studies that link maternal obesity to offspring metabolic
disease are of increasing importance to healthcare systems as the prevalence of obesity worldwide has
reached unprecedented rates over the last several decades [30]. The WHO estimates that about 40% of
men and women over the age of 18 were overweight or obese in 2016, and that proportion continues
to rise [30]. More specific to pregnancy outcomes and in line with data from most industrialized
nations, Health Canada reported in 2012–13 that 24% of Canadian women between 20–39 years of
age (child-bearing age) were obese, and 44% had a waist circumference that was predictive of high
risk for the development of health complications [31]. These reports suggest that the prevalence of
early-onset metabolic syndrome in offspring will only continue to increase alongside the rising rates of
maternal obesity.
Recent animal models utilizing dietary interventions in obese pregnancies have highlighted that
body composition metrics may not be the most accurate predictors of offspring future metabolic health
and that maternal gestational diet is an important influence (Table 1). For example, in sheep models of
gestational overfeeding-induced obesity a maternal dietary intervention early in gestation resulted in
lowered circulating plasma triglyceride levels (improved lipid metabolic function) as well as decreased
plasma insulin levels (improved glucose metabolism) in fetuses from obese pregnancies at both mid
and late gestation [27]. Additionally, NHP data suggest that there are vast differences in the metabolic
health of fetuses from obese mothers that consume different diets during gestation [28,29,32]. McCurdy
et al. (2009) identified that a diet reversal to a control diet in obese pregnant Japanese macaques was
sufficient to improve liver steatosis in third trimester fetuses, suggestive of a decreased risk of postnatal
NAFLD. Subsequent studies described reductions in maternal and fetal dyslipidemia and oxidative
stress in diet-reversed obese pregnancies leading to benefits in fetal liver development during the
third trimester [32]. Additionally, improved third trimester pancreatic islet vascularization has been
reported and highlights that these offspring would be less susceptible to later-life development of type
2 diabetes mellitus [29]. These NHP studies highlight that maternal gestational obesity alone may not
best predict offspring metabolic health and suggest that gestational diet is important in determining
metabolic health risk in the obesity-exposed offspring.
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Rodent models of obese pregnancy have also demonstrated the benefits of gestational diet
reversals (Table 1). For example, the male offspring of obese rats given a dietary intervention during the
gestational period have been found to have improved metabolic outcomes including improved insulin
sensitivity both neonatally and into adulthood [33]. However, additional rodent studies highlight that
a diet-reversal during pregnancy may not be sufficient to reverse the effects of maternal pre-pregnancy
obesity, as observed in sheep and NHP models. For example, mouse embryos transferred at the 2-cell
stage from high-fat-fed dams to control fed dams displayed poor in utero growth and neonatal catch-up
growth, as well as an altered expression of imprinted genes that have been associated with obesity
development suggesting that oocytes may be primed for adverse development as a direct result of
poor maternal diet pre-conception [34]. These findings are supported by other rodent models that
report poor liver and skeletal muscle mitochondrial health at post-natal day 35 in offspring exposed
to maternal pre-pregnancy obesity [35,36]. Specifically, hepatic tissue of rat offspring born to obese
dams displayed a marked decrease in the protein expression of markers of mitochondrial health
and biogenesis despite both control and obese dams being fed a control diet during the gestational
period [36].
The presence of the conflicting data between rodent and larger mammal (sheep and NHP) models
may simply arise from physiological differences between these species. For example, the longer
gestational period of sheep and NHP, and the fact that these species, like humans, have largely prenatal
developmental processes potentially underlies the differential impacts of a gestational diet reversal
intervention on fetal growth and development [37,38]. Further studies must be conducted to fully
understand whether dietary changes during human pregnancy are sufficient to reverse insults from a
poor maternal diet as in the NHP model and some rodent models or if human oocytes are ‘primed’
for metabolic disease with pre-gestational obesity exposure. Overall, these NHP and rodent studies
demonstrate that maternal diet prior to conception and during pregnancy has a profound impact of
the metabolic health of the offspring.
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Table 1. Summary of diet fat or feeding treatments utilized in animal models of maternal diet-induced gestational obesity and gestational high-fat exposure with and
without diet reversal.
Animal Model

Dietary Fat (% Caloric Intake)

Pre-Gestational
Obesity

Pre-Conception Diet
Exposure

Gestational Diet Exposure

Maternal Diet Reversal

Offspring Weaning

Reference

C57/B6 mice

60% High fat diet (HFD)
25% fat control diet

HFD-induced
obesity

10–12-week HFD
exposure before
pregnancy

HFD maintained through
pregnancy and lactation

Yes—2-cell stage
embryo transfer

Weaned onto control diet

Sasson [34]

C57/B6 mice

45% HFD
10% fat control diet

HFD-induced
obesity

Diet commenced at 4
weeks; breeding at 10
weeks

HFD through pregnancy

No

Randomly assigned HFD
or control diet

Elahi [20]

C57/BL6 mice

32% HFD
11% fat control diet

HFD-induced
obesity

8-week pre-conception
HFD-exposure

HFD through pregnancy

No

Fetal collections

Jones [17]

C57/B6 mice

16% HFD
control diet 3% fat

Diet-induced
obesity

6-week diet exposure
pre-conception

HFD maintained through
pregnancy and weaning

No

Pups weaned onto
standard chow

Samuelsson [22]

C57/B6 mice

High trans-fat diet (6% partially
hydrogenated vegetable oil +
1% soybean oil)
7% soybean oil control diet

No pre-pregnancy
obesity

No HFD exposure
pre-conception

High trans-fat diet through
pregnancy and weaning
only

No

Weaned onto control diet

de Velasco [39]

Sprague-Dawley
Rats

60% HFD
24% fat control diet

HFD-induced
obesity

HFD commenced
Postnatal day (PND) 24;
breeding PDN 120

HFD throughout pregnancy

No

Weaned onto control diet

Srinivasan [18]

Sprague-Dawley
Rats

140% overfeeding model

Overfeeding-induced 3-week overfeeding prior
obesity
to conception

Overfeeding discontinued
during pregnancy

Yes—dams switched to
control feeding through
pregnancy and lactation

Randomly weaned onto
control (17% fat) or HFD
(45% fat)

Borengasser [35]

Sprague-Dawley
Rats

140% overfeeding model

Overfeeding-induced 3-week overfeeding prior
obesity
to conception

Overfeeding discontinued
during pregnancy

Yes—dams switched to
control feeding through
pregnancy and lactation

Randomly weaned onto
control (17% fat) or HFD
(45% fat)

Borengasser [36]

Wistar Rats

45% HFD
18% fat control diet

HFD-induced
obesity with
pre-gestational
HFD exposure

Wistar Rats

38% HFD-diets
15% fat control diet

No pre-pregnancy
obesity

Pre-conception
HFD—commenced PND
22; breeding at PND 120
Pregnancy and lactation
HFD—commenced at
breeding and maintained
through lactation)

HFD through pregnancy

No

Randomly assigned HFD
or control diet

Howie [21]

No HFD exposure
pre-conception

HFD during pregnancy
only; cross-fostered to lean
dams during lactation

No

Weaned onto control diet;
HFD exposure at 8 weeks

Dong [40]
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Table 1. Cont.
Animal Model

Dietary Fat (% Caloric Intake)

Pre-Gestational
Obesity

Pre-Conception Diet
Exposure

Gestational Diet Exposure

Maternal Diet Reversal

Offspring Weaning

Reference

Wistar Rats

20% lard supplement in HFD
5% fat control diet

HFD-induced
obesity

HFD exposure from PND
21 to breeding at PND 120

HFD maintained through
pregnancy and lactation

Yes—diet intervention
back to control diet at
PND 90

Not specified

Zambrano [33]

Sheep

155% overfeeding model

No pre-gestational
obesity

Overfeeding commenced
gestational day 115

Overfeeding from
gestational day 115 to
gestation (~day 150)

No

Control diet during
lactation and weaning

Philip [26]

Sheep

150% overfeeding model

Overfeeding-induced
60-day overfeeding
obesity
exposure before mating

Overfeeding through
gestation, control diet
during lactation

No

control diet

Long [25]

Sheep

150% overfeeding model

60-day overfeeding
Overfeeding-induced
obesity
exposure before mating

Overfeeding until fetal
collection

No

Fetal collection

Zhu [41]

Sheep

150% overfeeding model

Overfeeding-induced
60-day overfeeding
obesity
exposure before mating

Overfeeding continued
through pregnancy (with no
intervention)

Yes—150% overfeeding
until gestational day 28
(with obesity
intervention)

Fetal collection

Tuersunjiang [27]

Japanese Macaque

36% HFD
14% fat control diet

HFD-induced
obesity

4–7-year HFD exposure
pre-conception

HFD maintained through to
fetal collections at
gestational day 130

Yes—diet reversal 3
months prior to
breeding

Fetal collection

Salati [42]

Japanese Macaque

32% HFD
14% fat control diet

HFD-induced
obesity

2–4-year pre-gestational
HFD induced obesity

HFD, or diet-reversal
through pregnancy

Yes—pre-conception
diet reversal on
subsequent pregnancy

Weaned onto mothers
gestational diet

McCurdy [28]

Japanese Macaque

32% HFD
14% fat control diet

HFD-induced
obesity

4–7-year pre-gestational
HFD exposure

HFD, or diet reversal
through pregnancy

Yes—switched back to
control diet in 5th
breeding season

Weaned onto in utero or
reverse diet

Pound [29]

Japanese Macaque

32% HFD
14% fat control diet

HFD-induced
obesity

2–9-year pre-conception
HFD exposure

HFD, or diet reversal
through pregnancy

Yes—switched back to
control diet in 9th
breeding season

Fetal collections

Wesolowski [32]
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4. Maternal Dietary Fat Consumption and Offspring Metabolic Health
Human population data have suggested that circulating maternal free fatty acids levels
are predictive of offspring metabolic health risks independent from measures of maternal body
composition, highlighting the importance of dietary lipids during gestation [43]. Additionally,
in animal-based studies, dietary fat components are altered in obese pregnancy dietary interventions
further highlighting that fats themselves are important in promoting the development of metabolic
disorders in exposed offspring.
Different FA species have varying impacts on metabolic health based on the length of the FA chain
(short-, medium-, long or very long-chain FA) as well as on the degree of saturation of the FA [44].
For example, a diet rich in cis-monounsaturated FA species (MUFAs) and polyunsaturated fats (PUFAs)
has been associated with increased levels of High-Density Lipoprotein (HDL), the “good cholesterol”,
and thus a healthier lipid metabolic profile [45]. More importantly, omega-3 PUFAs have also been
linked to improvements in metabolic health and function and may be an important factor in preventing
insulin resistance and type 2 diabetes in obese populations [46,47]. In contrast, a high consumption of
trans-unsaturated FA species has been found to lower serum levels of HDL and promote a less healthy
metabolic profile [45]. Additionally, a high consumption of saturated FA species has been associated
with poor metabolic profiles including increased serum levels of triglycerides, free cholesterol and
low-density lipoprotein (LDL), the “bad cholesterol” [48].
More importantly, consumption of certain FA species during pregnancy has been suggested to
promote the development of metabolic disorders in the offspring. For example, studies in rodent
model systems have highlighted that maternal diets comprised of different saturated FA chain lengths
have varying impacts on offspring later-life metabolic health [40]. Specifically, gestational diets that
were overabundant in medium chain length FA species from coconut oil (55% of FA species C14:0
or shorter) resulted in decreased offspring obesity development compared to offspring exposed to a
maternal overconsumption of longer-chain FA species from soybean oil (all FA C16:0 or longer) [40].
Additional rodent models have demonstrated that maternal diets rich in trans-unsaturated FA species
adversely affect offspring liver mitochondrial oxidative function, as well as increase circulating levels
of triglycerides, highlighting an overall dysregulation of hepatic lipid handling [39]. These studies
further highlight that maternal dietary fats are an important independent factor in offspring risk for
metabolic disease development.
To determine the impact of maternal dietary fat content upon fetal health outcomes in
human populations, it is important to fully understand the diet consumption patterns of pregnant
women. More importantly, it is necessary to understand how these maternal diets deviate from the
recommendations of government health agencies to provide insight into possible dietary interventions
that can reduce offspring metabolic health complications. Canada’s food guide for example,
recommends that pregnant women only consume a small amount (1–3 tbsp) of saturated fat each
day. In addition to limiting saturated fat intake, it is also suggested that these less healthy FAs should
be replaced with more omega-3 and -6 PUFAs. Specifically, for pregnant women, Health Canada
guidelines suggest consumption of at least 200 mg of Docosahexaenoic acid (DHA) (an omega-3 PUFA),
as this FA is necessary for proper fetal brain development [49]. However, despite these guidelines,
analysis of dietary consumption patterns suggests that a majority of pregnant women consume diets
that greatly deviate from food guide recommendations [50]. It is estimated that, on average, one-third of
total caloric intake in pregnant women is from lipid sources, and while this total fat intake does not
always exceed recommendations, the specific FAs that constitute total lipid intake in these women is
not ideal [50–52]. Specifically, these women have been found to consume diets that are calorie-dense
but low in nutrients, overabundant in long-chain saturated FA and lacking in important unsaturated
FA species such as DHA [52–54].
Overall, an increased maternal consumption of saturated FA and limited intake of omega-3 PUFAs
during pregnancy may be an important in utero insult that predisposes the offspring to metabolic
complications early in life.
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5. The Impact of Diet and Obesity upon the Placenta
The placenta is a transient organ composed of a heterogeneous population of cells that facilitates
hormone production, fetal immunity and all gaseous, nutrient and waste transport between maternal
and fetal circulation. It consists of two distinct but important populations of trophoblast cells,
extravillous trophoblasts (EVTs) and villous trophoblasts that arise from the outer trophectoderm layer
of the pre-implantation blastocyst. EVTs invade into the uterine wall to establish the maternofetal
blood connection and anchor chorionic villi to the uterine wall, while the villous trophoblast cells
of the chorionic villi act as a transport layer and comprise the barrier between maternal and fetal
blood supplies. The villous trophoblast layer is comprised of two unique cell population: underlying
progenitor cytotrophoblast (CT) cells and fused multi-nucleated syncytiotrophoblast (SCT) cells [55].
The CT and SCT cells of the villous trophoblast layer have been identified as the most metabolically
active within the placenta, and importantly maternal gestational obesity has also been identified
to negatively impact these cells [55–59]. Specifically, maternal obesity is often associated with
increased inflammation in placental tissues highlighted by increased pro-inflammatory cytokine
abundance and macrophage accumulation that can be detected as early as midgestation [41,60,61].
Additionally, maternal gestational obesity has been linked with a decreased expression of markers
of mitochondrial replication, and an overall reduction in electron transport chain activity (oxidative
function) leading to reduced placental ATP levels [36,56,62]. Impairments in placental functional
processes are thought underlie the aberrant fetal programming that primes obesity-exposed offspring
for metabolic dysfunction and ultimately metabolic disease early in life [63]. For example, NHP models
have demonstrated reduced placental vascular function and increased placental inflammation
with maternal obesity that can be improved with maternal diet reversal [42]. In turn, these diet
reversal-induced improvements in placental function may underlie the previously observed alterations
to offspring lipid and glucose metabolism [28,29,32,42]. Understanding specifically how maternal
dietary fat consumption may modulate placental lipid processing functions—including lipid transport,
esterification and oxidation—and what these changes mean for the developing fetus, will provide a
better understanding of the mechanisms underlying early-onset metabolic disease.
In vitro cell-based analysis of the placentamay allow for such insight into the effects of maternal
dietary intervention onlipid processing functions For example, CT cells have been cultured from term
human placentae following planned, non-laboring Caesarian-section births and utilized to examine
placental metabolic function in obese pregnancies with and without a dietary intervention [64,65].
The isolated effects of individual lipid species on placental lipid processes, independent from maternal
body composition and maternal gestational diet can also be examined through the use of immortalized
villous trophoblast cell lines that are available for commercial purchase. One such cell line is the
BeWo cell line, which has been demonstrated as a model of placental barrier function and has been
extensively utilized to examine the isolated effects that individual PUFA species have on placental
lipid transport [66,67].
6. Regulation of Placental Lipid Transport in Obesity and the Impact of Dietary Fats
The human placenta has an extensive ability to uptake lipid species and shuttle them and their
metabolic byproducts into fetal circulation. Proteomic analysis of term primary human trophoblast
(PHTs) has revealed that the placenta expresses lipid transport proteins on both the apical microvillous
(maternal-facing) and basolateral (fetal-facing) membranes [68]. Specifically, Fatty Acid Transport
Proteins 1, 2 and 4 (FATP1, FATP2, FATP4); Fatty Acid Binding proteins 1 and 3 (FABP1, FABP3) as
well as Fatty Acid Translocase (FAT/CD36) are expressed in the human placenta [68–71]. In addition,
isolated PHTs have demonstrated activity of Lipoprotein Lipase (LPL) indicating that lipid species
packaged as triglycerides in lipoproteins (HDL and LDL) can be processedby the placenta [72,73].
The FATPs as well as FAT/CD36 are localized on both the basolateral and apical placental
membranes and are involved in transporting a wide range of FA species across the placenta [68,74].
The presence of these transporters on both membranes suggests a bidirectional transfer of NEFAs
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can occur to respond to the changing nutrient demands of both mother and developing fetus [68,74].
In contrast, FABP transporters that demonstrate preferential binding for PUFA species are largely
localized to the maternal-facing apical membranes of the placenta [41,64]. This suggests that PUFA
species are transported unidirectionally across the placenta into the fetal circulation in order to
support and prioritize proper fetal brain development [68,75]. Similar to PHTs, the BeWo cell line
has demonstrated the ability to uptake and transport dietary NEFAs [76]. Specifically, this cell line
has been shown to express the lipid transporters: FATP1, FATP4, FAT/CD36 as well as FABP1 and
FABP3 [76,77]. As BeWo cells express the same lipid transport proteins as PHTs, they may represent a
viable model for studying placental barrier function and lipid transport, although caution must be
taken with interpretation of data from immortalized cell lines.
Maternal obesity during pregnancy has been associated with an altered expression and activity
of the lipid transporters in the placenta. Specifically, an increase in the activity of LPL and mRNA
expression of FAT/CD36 in conjunction with diminished mRNA levels of FATP1, FATP4 and FABP3
as well as reduced protein expression of FABP3 have been observed with increased maternal
adiposity [72,73] (Figure 1). The observed increases in the activity and expression of placental
LPL and FAT/CD36 may facilitate increased lipid transport into fetal circulation and could potentially
explain the increased prevalence of LGA offspring in obese pregnancies. In contrast, the specific
reduction in the expression of FATP and FABP transporters may simply reflect that the placenta is
attempting to modulate lipid transportto the developing fetus under conditions of lipid overload.
The notion that the placenta is able to modulate materno-fetal lipid transport in response to nutritional
state is supported by recent NHP experiments that identified increased protein expression of FATP and
FABP transporters under conditions of maternal nutrient restriction [78].
The relative influences that individual dietary FAs have on obesity-mediated altered placenta lipid
transport must be understood to predict how maternal diet interventions may impact fetal metabolic
disease. While almost one-third of the total lipid consumption of pregnant women is saturated fats,
current research into the effects of individual NEFA supplementation on placental lipid transport
has largely emphasized the effects of dietary PUFAs. Cell culture experiments conducted with the
BeWo cell line have found that a 24-h exposure to 100-µM concentrations of individual unsaturated
NEFAs (Oleate, DHA, and Arachidonic Acid (AA)) has no influence on placental FATP expression [76].
Similarly, there were no significant alterations in PHT FATP expression from women who took DHA
supplements during the third trimester [79]. PUFAs may in contrast, have an ability to alter the
expression of FABP transporters within the placenta and specifically AA has been found to increase the
expression of FABP3 in BeWo cells following after 24 h in culture [77] (Figure 1). These specific increases
in the expression of FABP3 in AA-treated BeWo cells may simply be reflective of the preferential
transport of PUFA species by placental FABPs, [41,64].
Future placental research must increasingly focus on the effects of dietary saturated fats to elucidate
if a maternal saturated fat overconsumption independent of body composition leads to increased
materno-fetal lipid transport via LPL and FAT/CD36 mediated transport. Furthermore, understanding
the molecular mechanisms that potentially regulate this increased materno-fetal lipid transport could
lead to the development of pharmacological inhibitors to better modulate in utero growth.
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Figure 1. Summary description of alterations to the placental lipid processing functions of fatty acid
(FA) transport, esterification and beta-oxidation under conditions of (A) maternal obesity and (B)
with maternal diet improvement. Maternal gestational obesity has been associated with increased (↑)
transplacental lipid transport (highlighted by increased expression of lipoprotein lipase (LPL) and
fatty acid translocase (FAT/CD36) as well as decreased (↓) expression of fatty acid transport proteins
(FATP) and fatty acid binding proteins (FABP)), increased placental lipid esterification and lipid droplet
formation as well as decreased placental mitochondrial beta-oxidation with concomitant increased
peroxisomal beta-oxidation. These changes are understood to be important in utero insults that program
the development of early-life metabolic disease in the offspring from obesity-exposed pregnancies.
Improved maternal diet under conditions of obesity, such as with consumption of a ‘pacific diet’ or
use of dietary polyunsaturated FA (PUFA) supplements, have been associated with reduced placental
steatosis and improved placental beta-oxidative function (increased mitochondrial beta-oxidation with
simultaneous decreased peroxisomal beta-oxidation).

7. Obesity, Diet and Placental Lipid Accumulation
The villous trophoblast cells of the placenta not only have the capability to uptake and transfer
NEFAs from maternal circulation to the fetus, but also to store them as lipid droplets for future
metabolic needs [80–82]. Analysis of the activity of FA transport proteins on placental membranes has
indicated that placental lipid uptake is greater on maternal-facing membranes than on fetal-facing
membranes, highlighting that placental lipid storage and/or metabolism is an important aspect of
placental lipid processing [82]. More recently, CT cells were demonstrated to be the sole location of lipid
esterification in cultured PHTs following treatment with fluorescent-conjugated FA derivatives [83].
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This suggests that the CT cells of the villous trophoblast layer may be more important than SCT cells
for lipid metabolic function in the placenta and may be a potential target of future pharmacological
therapies [83].
Maternal gestational obesity has been well demonstrated to alter placental lipid storage resulting in
a pathological accumulation of lipid droplets (steatosis) at term, suggesting that placental lipid droplets
may be a mechanism by which the placenta modulates FA transfer to the fetus [82,84–87] (Figure 1).
Analysis of the composition of these lipid droplets has demonstrated that saturated FAs and MUFAs are
the predominate lipid species that are stored in obese placentae, [88]. The increase in lipid esterification
and lipid droplet formation in obese placentae is potentially the result of increased formation of MUFA
species via Stearoyl-CoA Desaturase (SCD-1) [85]. SCD-1 is an enzyme that is overexpressed within
the obese placenta and converts the saturated FAs palmitate (16:0) and stearate (18:0) into less the
lipotoxic MUFAs palmitoleate (16:1n7) and oleate (18:1n9), respectively [89]. The formation of MUFA
species via SCD-1 has been previously been identified as a precursor step in the activation of WNT
signaling proteins via palmitoylation [90]. More importantly, increased activity of WNT signaling
proteins is involved in the pathology of placental steatosis in obesity-prone rats [91].
Maternal dietary supplementation with omega-3 PUFAs alone has been demonstrated to decrease
placental lipid accumulation at term in obese pregnancies [86] (Figure 1). In addition, human population
data have demonstrated that obese women from pacific regions such as Hawaii who naturally consume
greater levels of omega-3-rich fatty foods, such as fish, have less severe placental steatosis than obese
women from landlocked areas such Ohio who consume diets less plentiful in omega-3 fats [85,92]
(Figure 1). These studies further highlight that maternal diet is an important regulator of placental
lipid processing independent from maternal body composition. However, as previously stated,
lipid esterification is also an important regulator of transplacental lipid transport. Thus, an improvement
in placental steatosis with omega-3 PUFA supplements without correcting an underlying maternal
overconsumption of saturated fats may be harmful to the fetus through increased transplacental lipid
transport. In fact, there may be an increased risk that offspring are born LGA in pregnancies that are
supplemented with omega-3 PUFA, which itself may promote the development of later life metabolic
disease [93,94]. Overall, a simple dietary supplementation may not be sufficient to improve adverse
fetal outcomes, and a more rigorous dietary intervention may be needed in women who overconsume
saturated fats.
8. Diet and Placental Lipid Oxidation and Acylcarnitine Production in the Obese Environment
The dietary FA that are transported into the villous trophoblast cells from maternal circulation
can additionally be metabolized via mitochondrial beta-oxidation to produce ATP necessary for the
placenta to perform its biological functions. In brief, mitochondrial beta-oxidation occurs through 4
enzymatic steps in which the carbon backbone of the FA species is shortened to produce acetyl-CoA
that can enter The Citric Acid Cycle.
Immunohistological staining of isolated placental cells and western blot protein analysis of term
and early gestation human placental explants has revealed that villous trophoblast cells express enzyme
isoforms for all enzymatic steps in the mitochondrial beta-oxidation pathway. Both SCT and CT cells
are found to express the Acyl-CoA dehydrogenase isoforms very-long-chain acyl-CoA dehydrogenase
(VLCAD), long-chain acyl-CoA dehydrogenase (LCAD), and medium-chain acyl-CoA dehydrogenase
(MCAD); enolyl-CoA hydratase; the 3-hydroxyacyl-CoA dehydrogenase enzyme isofroms short-chain
L-3 hydroxyacyl-CoA dehydrogenase (SCHAD) and long-chain L-3 hydroxyacyl-CoA dehydrogenase
(LCHAD); as well as the 3-ketoacyl-CoA thiolase enzyme isoforms long-chain 3-ketoacyl-CoA thiolase
(LKAT) and short-chain 3-ketoacyl-CoA thiolase (SKAT) [95–97]. It is of particular interest to note that the
expression levels of these beta-oxidation enzymes within placental explants is similar to that of skeletal
muscle—a tissue known to be highly dependent on beta-oxidation for ATP production—highlighting
that FA oxidation is critical for placental [95].Additionally, the ability of placental mitochondria to utilize
lipid substrates for ATP production has been demonstrated to vary over gestation [97]. Specifically,
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mid-gestational placental explants display an elevated expression of mitochondrial beta-oxidation
enzymes compared to term samples, indicating that the capacity of the placenta to utilize FA as a
metabolic substrate diminishes as pregnancy progresses [97]. These findings suggest that the fetus
may be more susceptible to influences from a maternal diet overabundant in saturated FA during
late gestation when the placenta limits FA oxidation and increases trans-placental lipid transport to
support rapid fetal growth.
Independently, maternal gestational obesity has been shown to impede the ability of term placental
mitochondria to oxidize FA species for energy (ATP) production [85,98] (Figure 1). Observed decreases
in intra-placental concentrations of acylcarnitine species (a marker of beta-oxidation) combined
with an overall reduction in mitochondrial content within term obese placentae suggests that
the maternal environment can negatively impact placental beta-oxidation activity [85]. However,
while beta-oxidation primarily occurs within the mitochondria, placental peroxisomes have also
been found to express enzymes for FA beta-oxidation [65,99,100]. Specifically, the enzymes involved
in peroxisomal beta-oxidation are acyl-CoA oxidases (ACOX), D-bifunctional protein (DBP) and
3-ketoacyl-CoA thiolases [99,101]. In brief, peroxisomal beta-oxidation shortens long-chain FA species
into acetyl-CoA and short-chain acyl-CoAs such as octanoyl-CoA which can then be exported into the
mitochondria for complete oxidation [99,101]. More importantly, environmental cues such as fatty
acid overabundance in obesity have been associated with increases in both the size and number of
peroxisomes [85,102]. Additionally, maternal obesity has been linked to specific increases in the mRNA
expression of peroxisomal beta-oxidation enzymes, suggesting that peroxisomal beta-oxidation is a
major component of placental lipid handling in obese pregnancies [85] (Figure 1). Obese placentae
were further found to have greater rates of oxidation of radio-labelled palmitate following treatment
with etomoxir (a mitochondrial beta-oxidation inhibitor) than non-obese placentae highlighting that
increases in peroxisomal beta-oxidation may act to modulate lipid oxidation in obese pregnancies with
poor mitochondrial function [85]. Overall, these results suggest that the balance between mitochondrial
and peroxisomal beta-oxidation in the placenta is disrupted by obesity.
Maternal diet has been identified to impact placental lipid oxidative function in some obese
women. Specifically, obese Hawaiian women, who consume the Pacific diet, have been found to have
similar mRNA expression levels of mitochondrial and peroxisomal beta-oxidation enzymes as lean
Hawaiian women [92] (Figure 1). This may suggest that the increased PUFA content of the Pacific
diet could moderate the balance between mitochondrial and peroxisomal lipid oxidation. In contrast,
dietary omega-3 PUFA supplementation in obese pregnancies from landlocked areas (Ohio) was not
linked to alterations in mRNA expression of mitochondrial and peroxisomal beta-oxidative enzymes [86].
Additionally, omega-3 PUFA treatments did not alter [3 H]palmitate oxidation rates in cultured villous
trophoblast cells from otherwise healthy obese Ohioan women [86]. While PUFA supplementation
studies have highlighted some favourable outcomes, further studies of the impact upon mitochondrial
and peroxisomal beta-oxidation pathways are warranted. Furthermore, placental beta-oxidation
biomarker signatures must be identified in order to appropriately monitor the effects of any dietary
intervention in real time during gestation, especially in women from landlocked areas.
One potential method to quantify placental beta-oxidative function is to examine the acylcarnitine
profiles of maternal blood products. Under normal physiological conditions, complete beta-oxidation
occurs whereby all carbon atoms in the FA backbone are converted into acetyl-CoA molecules that are
oxidized for ATP production [95,96]. However, under pathological conditions such as lipid overload,
mitochondrial beta-oxidation may become incomplete resulting in accumulation of shortened chain
acyl-CoA molecules within the mitochondrial matrix that may then be exported into circulation [103,104].
Analysis of differences in acylcarnitine profiles has previously been utilized to predict the presence of
aberrant metabolic function in tissues including cardiac and skeletal muscle [105–109]. Thus, analysis of
blood acylcarnitine profiles of mothers who consume poor diets throughout the gestational period
may allow for the real-time identification of specific placental-derived acylcarnitine species that are
predictive of aberrant placental mitochondrial beta-oxidative function.
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Acylcarnitine profiles have previously been examined as potential biomarkers for the early
detection of other placental diseases such as pre-eclampsia [110,111]. Specifically, potential acylcarnitine
biomarkers for the early detection of pre-eclampsia were found in both maternal serum and
plasma [110,111]. In addition, acylcarnitines have also been examined as potential non-invasive
biomarkers to examine placental metabolic function under conditions of maternal obesity [85,112,113].
As this field of investigation develops, it is important to note that these studies highlight that different
maternal blood fractions may have differing capabilities to estimate placental metabolic function.
For example, increases in some short chain acylcarnitine species are reported in maternal serum with
increasing BMI [112], while no differences are found in acylcarnitine profiles in maternal plasma [113].
Accumulation of shortened acylcarnitine species has also previously been linked to an increased
expression of pro-inflammatory molecules [104]. For example, mouse macrophage cells cultured
with short-chain acylcarnitine species displayed a marked increase in the phosphorylation of the
downstream effector proteins JNK and ERK which are involved in the signaling cascade of many
inflammatory peptides [104]. If a maternal diet high in saturated fat can lead to incomplete placental
beta-oxidation that promotes an inflammatory response, acylcarnitine analysis may be beneficial
in explaining the presence of increased placental inflammation that often accompanies maternal
obesity [114].
Overall, acylcarnitine analysis may represent a relatively unexplored field in placenta physiology.
Analysis of differences within these profiles of obese and lean women may allow clinicians to diagnose
placental mitochondrial dysfunctions in conjunction with inflammatory responses early during the
gestation period. In turn, acylcarnitine biomarkers may allow clinicians to monitor the impact of
dietary interventions on placental lipid handling during gestational period and modulate the course of
treatment to limit the risks of offspring development of later life disease.
9. Conclusions
A maternal consumption of a diet high in saturated FA species and low in PUFA species during
the gestational period may promote adverse placental function that underlies the development of
placental and fetal metabolic dysfunction, independent to maternal body composition. Understanding
the mechanisms that underlie placental metabolic dysfunctions associated with dietary fat in obese
pregnancies and the accompanying offspring metabolic disorders will require a robust understanding
of placental lipid transport, esterification and oxidation (Figure 1). A greater understanding of these
processes will yield information that will provide frameworks from which to develop diagnostic tests
to monitor the efficacy of gestational dietary interventions. Proper implementation of gestational diet
improvements in obese women has the potential to limit future harm to the placenta and overall reduce
risk of early-onset metabolic disease development in obesity-exposed offspring.
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